Kairos Pharma, LTD. (KAPA) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
KAPA currently has 21M outstanding shares. with significant dilution risk as 24.7M authorized shares could dilute existing holders by 117.4%. The company has significantly diluted shareholders by 83.36% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 13, 2026 |
10-Q filing | 21.0M shares outstanding |
21M | 25M |
| Mar 31, 2026 |
10-K filing | 21.4M shares outstanding |
21M | 25M |
| Nov 14, 2025 |
10-Q filing | 20.2M shares outstanding |
20M | 25M |
| May 14, 2025 |
10-Q filing | 15.9M shares outstanding |
16M | 25M |
| Apr 22, 2025 |
S-1 filing: Kairos Pharma, Ltd. is offering up to 16,295,641 shares of common stock through an equity line of credit agreement and resale of shares held by Helena Global Investment Opportunities I Ltd. |
17M | 25M |
| Apr 15, 2025 |
10-K filing | 16.7M shares outstanding |
17M | 8.4M |
| Jan 29, 2025 |
S-1 filing: This S-1 filing registers 6,425,000 shares of common stock issuable upon exercise of warrants, including pre-funded warrants, common warrants and placement agent warrants, for resale by the selling stockholders. |
14M | 8.4M |
| Jan 17, 2025 |
8-K filing: Kairos Pharma, Ltd. closed on the sale of 2,500,000 pre-funded units to a PIPE Investor on January 16, 2025, for $3,497,500. They also issued warrants to placement agents for the offering. ($3.5M proceeds) |
13M | 1.9M |
| Jan 14, 2025 |
8-K filing: Kairos Pharma, Ltd. entered into a Securities Purchase Agreement with PIPE Investors to sell 2,500,000 common units at $1.40 per unit and pre-funded units at $1.399 per unit, expecting gross proceeds of $3.5 million. ($3.5M proceeds) |
13M | 1.9M |
| Nov 14, 2024 |
10-Q filing | 12.8M shares outstanding |
13M | 1.9M |
| Sep 27, 2024 |
8-K filing: Kairos Pharma, Ltd. entered into an advisory and consulting services agreement with CEO.CA Technologies Ltd. and a strategic advisory agreement with Belair Capital Advisors Inc. involving the issuance of 50,000 restricted stock units. |
11M | 1.9M |
| Sep 17, 2024 |
8-K filing: Kairos Pharma, Ltd. completed its initial public offering of 1,550,000 shares of common stock at $4.00 per share on September 17, 2024, receiving gross proceeds of $6,200,000 and issued warrants to the Underwriters. ($6.2M proceeds) |
11M | 1.9M |
| Aug 16, 2024 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Kairos Pharma, Ltd. |
11M | 1.9M |
| Jun 04, 2024 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock, par value $.001 per share, of Kairos Pharma, Ltd. We are offering 1,550,000 shares of our common stock and currently expect that the initial public offering price will be $4.00 per share. |
11M | 1.9M |
| May 24, 2024 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock by Kairos Pharma, Ltd. |
11M | 1.9M |
| May 20, 2024 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock for Kairos Pharma, Ltd. |
11M | 1.9M |
| May 13, 2024 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock by Kairos Pharma, Ltd. |
11M | 1.6M |
| May 01, 2024 |
S-1/A filing: This S-1/A filing details a proposed initial public offering of 1,550,000 shares of common stock at an assumed price of $4.00 per share. |
11M | 1.6M |
| Feb 14, 2024 |
S-1/A filing: This is a firm commitment initial public offering of shares of common stock of Kairos Pharma, Ltd. |
25M | 1.6M |
| Dec 07, 2023 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock by Kairos Pharma, Ltd. |
25M | 0 |
| Sep 29, 2023 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock by Kairos Pharma, Ltd. |
25M | 0 |